The Medicines Company: Improving Atherosclerotic Cardiovascular Diseases (ASCVD)

The Medicines Company ORION-10 Study for ASCVD
The Medicines Company (MDCO) announced positive topline results from the ORION-10 Phase 3 clinical trial in patients with atherosclerotic cardiovascular disease (ASCVD). The ORION-10 trial conducted with . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.